Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer

Journal of the National Cancer Institute

Volumn 106, Issue 10, 2014, Pages

  Schroen, Anneke T ^a   Slingluff, Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; EDITORIAL; EDUCATION; HEALTH CARE COST; HUMAN; INCOME; LUNG CANCER; PATIENT INFORMATION; PATIENT PARTICIPATION; PATIENT PREFERENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RACE; COLORECTAL TUMOR; DECISION MAKING; FEMALE; INTERPERSONAL COMMUNICATION; LUNG TUMOR; MALE; NOTE; PATIENT SELECTION;

COLORECTAL NEOPLASMS; COMMUNICATION; DECISION MAKING; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PATIENT SELECTION;

EID: 84930392165     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju265     Document Type: Editorial

References (11)

1. Institute of Medicine. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI cooperative group program.. Washington, DC: The National Academies Press; 2010.
2. Cassileth BR. Clinical trials: Time for action. J Clin Oncol. 2003;21(5):765-766.
3. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-2726.
4. Fisher B. On clinical trial participation. J Clin Oncol. 1991;9(11):1927-1930.
5. Schroen AT, Wang H, Petroni GR, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from US cooperative oncology groups. Clin Cancer Res. 2012;18(1):256-262.
6. Prescott RJ, Counsell CE, Gillespie WJ, et al. Factors that limit the quality, number and progress of randomized controlled trials. Health Technol Assess. 1999;3(20):1-143.
7. Grunfeld E, Zitzelsberger L, Coristine M, Aspelund F. Barriers and facilitators to enrollment in cancer clinical trials: qualitative study of the perspectives of clinical research associates. Cancer. 2002;95(7):1577-1583.
8. Ross S, Grant A, Counsell C, et al. Barriers to participation in randomized controlled trials: a systematic review. J Clin Epidemiol. 1999;52(12):1143-1156.
9. Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728-1733.
10. Ford JG, Howerton MW, Bolen S, et al. Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials. Evidence Report/Technology Assessment No. 122. (Prepared by the Johns Hopkins University Evidence-Based Practice Center under contract no. 290-02-0018). AHRQ Publication No. 05-E019-2.. Rockville, MD. Agency for Healthcare Research and Quality. June 2005.
11. Kehl KL, Arora NK, Schrag D, Ayanian JZ, et al. Discussion about clinical trials among patients with newly diagnosed lung and colorectal cancer. J Natl Cancer Inst. 2014;106(10):106(10): dju216 doi:10.1093/jnci/dju216.